生物治疗后的皮肤T细胞淋巴瘤极为罕见。本系统性综述的目的是研究生物制剂治疗后皮肤T细胞淋巴瘤（CTCL）的发展情况。针对曝露于生物制剂后发展CTCL的患者进行系统文献综述。本综述限制于英语文献，并排除动物研究，指南和协议。结合关键词使用控制词汇识别潜在的符合资格的标题。在执行之前，检索策略经过同行评审。28项研究揭示了62名曝露于生物制剂后发展CTCL的患者。其中44％为白种人，诊断年龄的中位数为56岁。76％的患者因为原发性炎症性皮肤病接受了生物制剂治疗。Dupilumab是队列中最多报告的制剂（占42％）。这些病例中，从生物制剂治疗开始到CTCL诊断的中位时间为4个月（范围：0-84个月）。真菌病样肿瘤（65％）和塞扎里综合征（10％）是最常见的CTCL亚型。21项（34％）患者的疾病仍在存活中，21名患者（34％）没有报道结局，十名患者（16％）存活且完全缓解，八名患者（13％）死于疾病，两名患者（3％）死于其他原因。虽然生物制剂可能在CTCL的发展中发挥作用，但为了明确他们的作用，需要进行更多方法学更加健全的研究（例如利用人口数据库的研究）。©2023年。本作者对Springer Nature Switzerland AG拥有排他许可。

Cutaneous T-cell lymphoma following biologic therapy is extremely rare.The aim of this systematic review was to investigate the development of cutaneous T-cell lymphoma (CTCL) following treatment with a biologic agent.A systematic literature review was performed for patients who developed CTCL after exposure to biologic therapy. Works were limited to English language and excluded animal studies, guidelines, and protocols. Potentially eligible titles were identified using controlled vocabulary in tandem with key words. The search strategy was peer-reviewed prior to execution.Twenty-eight total studies revealed sixty-two patients who developed CTCL following exposure to a biologic agent. Of these, 44% were Caucasian, and the median age at diagnosis was 56 years. Seventy-six percent of patients received biologic therapy for a primary inflammatory skin condition. Dupilumab was the most reported (42%) agent amongst the cohort. The median time from initiation of the biologic agent to diagnosis of CTCL in these cases was 4 months (range: 0-84). Mycosis fungoides (65%) and Sézary syndrome (10%) were the most common subtypes of CTCL diagnosed. Twenty-one (34%) patients were reported to be alive with disease, outcome was not reported in 21 patients (34%), ten patients (16%) were alive and in complete remission, eight patients (13%) died of disease and two patients (3%) died due to other causes.While biologic agents may have a role in the development of CTCL, in order to definitively elucidate their role, more methodologically robust studies (such as those that utilize population databases) would need to occur.© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.